

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
GRASSBERGER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/003511

FILED: 2 APRIL 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: SYNERGISTIC COMBINATIONS OF MACROLIDE T-CELL
MODULATOR OR IMMUNOSUPPRESSANT AND A RETINOID

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/003511, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614

Date: 9/23/05

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
PD/4-32802A
APPLICATION NO.

10/550358

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT
GRASSBERGER ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	02/098376	12/12/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Chaidemenos et al., "Combination of Cyclosporin A and Acitretin in Resistant Erythrodermic Psoriasis", Dermatology and Venereology, Vol. 11, pp. S290-S291 (1998).
AS	Connelly et al., "Treatment of Facial Angiofibromas with Topical Pimecrolimus and Tazarotene Gel", Journal of Investigative Dermatology, Vol. 121, No. 1, p. 0030 (2003).
AT	Kokelj et al., "Efficacy of Cyclosporine Plus Etretnate in the Treatment of Erythrodermic Psoriasis (Three Case Reports)", Journal of the European Academy of Dermatology and Venereology, Vol. 11, No. 2, pp. 177-179 (1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PD/4-32802A
APPLICATION NO.

10/550358

APPLICANT
GRASSBERGER ET AL.
FILING DATE

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Singh et al., "Oral Tazarotene and Oral Pimerolimus: Novel Oral Therapies in Development for Psoriasis", Journal of Drugs in Dermatology, Vol. 3, No. 2, pp. 141-143 (2004).
	DB	Tuyp et al., "Combination Therapy for Psoriasis with Methotrexate and Etretinate", Journal of the American Academy of Dermatology, Vol. 14, No. 1, pp. 70-73 (1986).
	DC	
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.